Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-04-22
2008-04-22
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07361643
ABSTRACT:
A method for inhibiting angiogenesis, including: administering a nucleoside, such as tunicamycin, in an amount effective to inhibit angiogenesis, to a patient in need of such treatment. A method for inhibiting angiogenesis, including: administering a nucleoside, which comprises glucosamine, in an amount effective to inhibit angiogenesis, to a patient in need of such treatment; wherein the nucleoside is administered for a period of time, subsequently the administration of the nucleoside is suspended for a period of time of at least about 1 week, and subsequently the administration of the nucleoside is resumed.
REFERENCES:
patent: 5382514 (1995-01-01), Passaniti et al.
patent: 5629340 (1997-05-01), Kuwano et al.
patent: 5760028 (1998-06-01), Jadhav et al.
patent: 5760029 (1998-06-01), Jadhav et al.
patent: 5766591 (1998-06-01), Brooks et al.
patent: 5807731 (1998-09-01), Van Meir et al.
patent: 5830880 (1998-11-01), Sedlacek et al.
patent: 5837682 (1998-11-01), Folkman et al.
patent: 5854205 (1998-12-01), O'Reilly et al.
patent: 5932611 (1999-08-01), Wuthier et al.
patent: 5945403 (1999-08-01), Folkman et al.
patent: 5981471 (1999-11-01), Papathanassiu et al.
patent: 5985839 (1999-11-01), Dupont et al.
patent: 5994309 (1999-11-01), Mazar et al.
patent: 6024688 (2000-02-01), Folkman et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6096730 (2000-08-01), Collins et al.
patent: 6114355 (2000-09-01), D'Amato
patent: 6121236 (2000-09-01), Ben-Sasson
patent: 6130231 (2000-10-01), Wityak et al.
patent: 6146824 (2000-11-01), Bar-Shavit
patent: 6150407 (2000-11-01), Tusé et al.
patent: 6153603 (2000-11-01), Sirén
patent: 6160166 (2000-12-01), Collins et al.
Presta et al., Cancer Research vol. 59, pp. 2417-2424.
Banerjee et al., Indian J. of Biochem. and Biophysics, vol. 30(6), pp. 389-394, see abstract.
Banerjee et al., Indian J. Biochem. and Biophysics, vol. 30(6), pp. 389-394, (1993).
Exp. Cell Research, vol. 198, pp. 191-200 (1992), submitted in IDS filed Jul. 16, 2001.
Cockerill et al., “Angiogenesis: Model and Modulators”,Int Rev Cytol, 159: 113-160 (1995).
Folkman et al., “Angiogenesis”,J Biol Chem, 267:10931-10934 (1992).
Beck et al., “Vascular Development: Cellular and Molecular Regulation”,FASEB J., 11:365-373 (1997).
Bussolino et al., “Molecular Mechanisms of Blood Vessel Formation”,TIBS, 22:251-256 (1997).
Folkman et al., “Induction of Angiogenesis During the Transition from Hyperplasia to Neoplasia”,Nature, 339: 58-61 (1989).
Friedlander et al., “Definition of Two Angiogenic Pathways by Distinct αvIntegrins”,Science, 270:1500-1502 (1995).
Liotta et al., “Cancer Metastasis and Angiogenesis: an Imbalance of Positive and Negative Regulation”,Cell, 64:327-336 (1991).
Saclarides et al., “Tumor Angiogenesis and Rectal Carcinoma”,Dis. Colon Rectum, 37:921-926 (1994).
Shweiki et al., “Patterns of Expression of Vascular Endothelial Factor (VEGF) and VEGF Receptors in Mice Suggest a Role in Hormonally Regulated Angiogenesis”,J. Clin. Invest., 91:2235-2243 (1993).
Vartanian et al., “Correlation of Intratumoral Endothelial Cell Proliferation with Microvessel Density (Tumor Angiogenesis) and Tumor Cell Proliferation in Breast Carcinoma”,Am. J. Pathol., 144:1188-1194 (1994).
Folkman et al., “Angiogenic Factors”,Science, 235:442-447 (1987).
Furcht, “Critical Factors Controlling Angiogenesis: Cell Products, Cell Matrix, and Growth Factors”,Lab. Invest., 55:505-509 (1986).
Denekamp, “Angiogenesis, Neovascular Proliferation and Vascular Pathophysiology as Targets for Cancer Therapy”,Br. J. Radiol., 66:181-196 (1993).
Nicolson, “Cancer Metastasis”,Sci. Am., 240:66-76 (1979).
Nagy et al., “Pathogenesis of Tumor Stroma Generation: a Critical Role for Leaky Blood Vessels and Fibrin Deposition”,Biochim Biophys. Acta, 948:305-326 (1989).
Moscatelli et al., “Angiogenic Factors Stimulate Plasminogen Activator and Collagenase Production by Capillary Endothelial Cells”,J. Cell Biol., 91:201a (1981).
Liotta et al., “The Significance of Hematogenous Tumor Cell Clumps in the Metastatic Process”,Cancer Res., 36:889-894 (1976).
Folkman, “Tumor Angiogenesis: Therapeutic Implications”,N. Engl. J. Med., 285:1182-1186 (1971).
Folkman, “Clinical Applications of Research on Angiogenesis”,N. Engl. J. Med., 333:1757-1763 (1995).
Harris et al., “Gene Therapy Through Signal Transduction Pathways and Angiogenic Growth Factors as Therapeutic Targets in Breast Cancer”,Cancer, 74:1021-1025 (1994).
Ingber et al., “Synthetic Analogues of Fumagillin that Inhibit Angiogenesis and Suppress Tumor Growth”,Nature, 348:555-557 (1990).
Hori et al., “Suppression of Solid Tumor Growth by Immunoneutralizing Monoclonal Antibody Against Human Basic Fibroblast Growth Factor”,Cancer Res., 51:6180-6184 (1991).
Kim et al., “Inhibition of Vascular Endothelial Growth Factor-induced Angiogenesis Suppresses Tumor Growth in vivo”,Nature, 362:841-844 (1993).
Millauer et al., “Glioblastoma Growth Inhibited in vivo by a Dominant-negative Flk-1 Mutant”,Nature, 367:576-579 (1994).
Brooks et al., “Integrin αvβ3 Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels”,Cell, 79:1157-1164 (1994).
Rak et al., “Progressive Loss of Sensitivity to Endothelium-derived Growth Inhibitors Expressed by Human Melanoma Cells during Disease Progression”,J. Cell Physiol., 159:245-255 (1994).
Hamada et al., “Separable Growth and Migration Factors for Large-cell Lymphoma Cells Secreted by Microvascular Endothelial Cells Derived from Target Organs for Metastasis”,Br. J. Cancer, 66:349-354 (1992).
Fox et al., “High Levels of uPA and pA-1 are Associated with Highly Angiogenic Breast Carcinomas”,J. Pathol., 170:388a (1993).
Polverini et al., “Induction of Neovascularization in vivo and Endothelial Proliferation in vitro by Tumor Associated Macrophages”,Lab. Invest., 51:635-642 (1984).
Frater-Schroder et al., “Tumor Necrosis Factor Type α, a Potent Inhibitor of Endothelial Cell Growth in vitro, is Angiogenic in vivo”,Proc. Natl. Acad. Sci(USA), 84:5277-5281 (1987).
Schreiber et al., “Transforming Growth Factor-α: a More Potent Angiogenic Mediator than Epidermal Growth Factor”,Science, 232:1250-1253 (1986).
Hockel et al., “Purified Monocyte-derived Angiogenic Substance (Angiotropin) Induces Controlled Angiogenesis Associated with Regulated Tissue Proliferation in Rabbit Skin”,J. Clin. Invest., 82:1075-1090 (1988).
Thornton et al., Human Endothelial Cells: Use of Heparin in Cloning and Long-term Serial Cultivation,Science, 222:623-625 (1983).
Dethlefsen et al., “Tumor Growth and Angiogenesis in Wild Type and Mast Cell Deficient Mice”,FASEB J., 4:A623 (1990).
Kandel et al., “Neovascularization is Associated with a Switch to the Export of bFGF in the Multistep Development of Fibrosarcoma”,Cell, 66:1095-1104 (1991).
Nguyen et al., “Elevated Levels of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of Bladder Cancer Patients”,J. Natl. Cancer Inst., 85:241-242 (1993).
Brown et al., “Increased Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and its Receptors in Kidney and Bladder Carcinomas”,Am J. Pathol., 143:1255-1262 (1993).
Goto et al., “Synergistic Effects of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor on the Proliferation and Cord Formation of Bovine Capillary Endothelial Cells within Collagen Gels”,Lab. Invest., 69:508-517 (1993).
Leibovich et al., “Production of Angiogenic Activity by Human Monocytes Requires an L-arginine
itric oxide-synthase-dependent Effector Mechanism”,Proc. Natl. Acad. Sci(USA),
Banerjee Dipak K.
Martinez Juan A.
Hoglund & Pamias PSC
Jiang Shaojia Anna
Krishnan Ganapathy
Rios Roberto J.
University of Puerto Rico
LandOfFree
Methods for inhibiting angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2769165